about
Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug designInhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma modelsInitial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.Heat shock protein 90 inhibition abrogates TLR4-mediated NF-κB activity and reduces renal ischemia-reperfusion injury.The novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells.Molecular imaging of EGFR and CD44v6 for prediction and response monitoring of HSP90 inhibition in an in vivo squamous cell carcinoma modelA novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation.Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib.Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer.First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors.Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas.Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.Re: First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors.Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumorsTotal synthesis of resorcinol amide Hsp90 inhibitor AT13387The HSP90 inhibitor onalespib potentiates 177Lu‑DOTATATE therapy in neuroendocrine tumor cells
P921
Q27663623-BDD473A3-31FD-4C8C-8063-39D7573364C3Q34677194-1C250162-DD29-4589-AC94-CCEA49832FB4Q35159149-6A77915E-0A39-4E81-B9BF-360115AF67A6Q35926013-C9E06376-DFD3-42C9-A983-7BA78F571354Q36546425-34352D3A-F7A8-4CAF-8F14-1FE4832FCF2AQ36762341-C9A7E814-F8D3-498E-9186-2A405D3248ABQ37327734-785DE060-DF08-4C7D-9D68-89459DDAF8CFQ38737681-921E373E-447D-4E5E-A3F3-17FC04C09CDBQ38769817-8CA58BDE-5422-47E4-A7E3-FB4A56D78C79Q38833685-761468D9-B2ED-449D-A698-BD53809B31A7Q39425771-ABE173B5-F096-466C-AEA4-007A6A41ECAAQ46570196-7FFB911D-51ED-4A46-91FD-414FB990FC13Q48210380-CC71FFB1-6127-4691-9FF0-B53E354088CCQ53792585-6B09F863-90A0-4BB8-BCD1-6049F6E19658Q54027806-B5074944-9E56-44C8-8D91-FD63B75EE2DAQ85393460-440219AD-FD14-44E8-BAE7-47CAF32FF41EQ85550006-037E1CDA-FC54-4EDC-964F-05ADF36B4DCEQ90868547-055F75AE-90CC-43B4-8D9C-CA80E369A3C9
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
onalespib
@en
type
label
onalespib
@en
altLabel
Onalespib
@en
prefLabel
onalespib
@en
P592
P638
P661
P662
P683
P2067
P231
912999-49-6
P233
CC(C)C1=C(C=C(C(=C1)C(=O)N2CC3=C(C2)C=C(C=C3)CN4CCN(CC4)C)O)O
P234
1S/C24H31N3O3/c1-16(2)20-11-21 ...... 12,16,28-29H,6-9,13-15H2,1-3H3
P235
IFRGXKKQHBVPCQ-UHFFFAOYSA-N
P274
C₂₄H₃₁N₃O₃
P3117
DTXSID80238485
P592
CHEMBL1214827
P652
Q7Y33N57ZZ